|
1.
|
Arndt CA and Crist WM: Common
musculoskeletal tumors of childhood and adolescence. N Engl J Med.
341:342–352. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar
|
|
3.
|
Ozaki T, Flege S, Kevric M, et al:
Osteosarcoma of the pelvis: experience of the Cooperative
Osteosarcoma Study Group. J Clin Oncol. 21:334–341. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Saeter G, Hoie J, Stenwig AE, Johansson
AK, Hannisdal E and Solheim OP: Systemic relapse of patients with
osteogenic sarcoma. Prognostic factors for long term survival.
Cancer. 75:1084–1093. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Tabone MD, Kalifa C, Rodary C, Raquin M,
Valteau-Couanet D and Lemerle J: Osteosarcoma recurrences in
pediatric patients previously treated with intensive chemotherapy.
J Clin Oncol. 12:2614–2620. 1994.PubMed/NCBI
|
|
6.
|
Ham SJ, Schraffordt Koops H, van der Graaf
WT, van Horn JR, Postma L and Hoekstra HJ: Historical, current and
future aspects of osteosarcoma treatment. Eur J Surg Oncol.
24:584–600. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Lin F, Zheng SE, Shen Z, et al:
Relationships between levels of CXCR4 and VEGF and blood-borne
metastasis and survival in patients with osteosarcoma. Med Oncol.
28:649–653. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Lee JA, Kim MS, Kim DH, et al: Relative
tumor burden predicts metastasis-free survival in pediatric
osteosarcoma. Pediatr Blood Cancer. 50:195–200. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Yang J, Yang D, Cogdell D, et al: APEX1
gene amplification and its protein overexpression in osteosarcoma:
correlation with recurrence, metastasis, and survival. Technol
Cancer Res Treat. 9:161–169. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Yin AH, Miraglia S, Zanjani ED, et al:
AC133, a novel marker for human hematopoietic stem and progenitor
cells. Blood. 90:5002–5012. 1997.PubMed/NCBI
|
|
11.
|
Weigmann A, Corbeil D, Hellwig A and
Huttner WB: Prominin, a novel microvilli-specific polytopic
membrane protein of the apical surface of epithelial cells, is
targeted to plasmalemmal protrusions of non-epithelial cells. Proc
Natl Acad Sci USA. 94:12425–12430. 1997. View Article : Google Scholar
|
|
12.
|
Yin S, Li J, Hu C, et al: CD133 positive
hepatocellular carcinoma cells possess high capacity for
tumorigenicity. Int J Cancer. 120:1444–1450. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Monzani E, Facchetti F, Galmozzi E, et al:
Melanoma contains CD133 and ABCG2 positive cells with enhanced
tumourigenic potential. Eur J Cancer. 43:935–946. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Terry J and Nielsen T: Expression of CD133
in synovial sarcoma. Appl Immunohistochem Mol Morphol. 18:159–165.
2009. View Article : Google Scholar
|
|
15.
|
Tirino V, Desiderio V, d’Aquino R, et al:
Detection and characterization of CD133+ cancer stem
cells in human solid tumours. PLoS One. 3:e34692008. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Li J, Liu W, Zhao K, et al: Diallyl
trisulfide reverses drug resistance and lowers the ratio of
CD133+ cells in conjunction with methotrexate in a human
osteosarcoma drug-resistant cell subline. Mol Med Report.
2:245–252. 2009.PubMed/NCBI
|
|
17.
|
Veselska R, Hermanova M, Loja T, et al:
Nestin expression in osteosarcomas and derivation of nestin/CD133
positive osteosarcoma cell lines. BMC Cancer. 8:3002008. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Song W, Li H, Tao K, et al: Expression and
clinical significance of the stem cell marker CD133 in
hepatocellular carcinoma. Int J Clin Pract. 62:1212–1218. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Horst D, Kriegl L, Engel J, Kirchner T and
Jung A: CD133 expression is an independent prognostic marker for
low survival in colorectal cancer. Br J Cancer. 99:1285–1289. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Zhang J, Guo X, Chang DY, Rosen DG,
Mercado-Uribe I and Liu J: CD133 expression associated with poor
prognosis in ovarian cancer. Mod Pathol. 25:456–464. 2011.
View Article : Google Scholar
|
|
21.
|
Qin Q, Sun Y, Fei M, et al: Expression of
putative stem marker nestin and CD133 in advanced serous ovarian
cancer. Neoplasma. 1–2. 2012.PubMed/NCBI
|
|
22.
|
Fan L, He F, Liu H, et al: CD133: a
potential indicator for differentiation and prognosis of human
cholangiocarcinoma. BMC Cancer. 11:3202011. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Li S, Li Z, Guo F, et al: miR-223
regulates migration and invasion by targeting Artemin in human
esophageal carcinoma. J Biomed Sci. 18:242011. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Kojima M, Ishii G, Atsumi N, Fujii S,
Saito N and Ochiai A: Immunohistochemical detection of CD133
expression in colorectal cancer: a clinicopathological study.
Cancer Sci. 99:1578–1583. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Tang N, Song WX, Luo J, Haydon RC and He
TC: Osteosarcoma development and stem cell differentiation. Clin
Orthop Relat Res. 466:2114–2130. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Wion D and Berger F: Cancer stem cells. N
Engl J Med. 355:2703author reply 2703. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Pardal R, Clarke MF and Morrison SJ:
Applying the principles of stem-cell biology to cancer. Nat Rev
Cancer. 3:895–902. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Liu B, Ma W, Jha RK and Gurung K: Cancer
stem cells in osteosarcoma: recent progress and perspective. Acta
Oncol. 50:1142–1150. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Gibbs CP, Kukekov VG, Reith JD, et al:
Stem-like cells in bone sarcomas: implications for tumorigenesis.
Neoplasia. 7:967–976. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Singh SK, Hawkins C, Clarke ID, et al:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E,
et al: Identification and expansion of human
colon-cancer-initiating cells. Nature. 445:111–115. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Niwa H, Miyazaki J and Smith AG:
Quantitative expression of Oct-3/4 defines differentiation,
dedifferentiation or self-renewal of ES cells. Nat Genet.
24:372–376. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Looijenga LH, Stoop H, de Leeuw HP, et al:
POU5F1 (OCT3/4) identifies cells with pluripotent potential in
human germ cell tumors. Cancer Res. 63:2244–2250. 2003.PubMed/NCBI
|
|
34.
|
Mitsui K, Tokuzawa Y, Itoh H, et al: The
homeoprotein Nanog is required for maintenance of pluripotency in
mouse epiblast and ES cells. Cell. 113:631–642. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Wang L, Park P and Lin CY:
Characterization of stem cell attributes in human osteosarcoma cell
lines. Cancer Biol Ther. 8:543–552. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Hermann PC, Huber SL, Herrler T, et al:
Distinct populations of cancer stem cells determine tumor growth
and metastatic activity in human pancreatic cancer. Cell Stem Cell.
1:313–323. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Adhikari AS, Agarwal N, Wood BM, et al:
CD117 and Stro-1 identify osteosarcoma tumor-initiating cells
associated with metastasis and drug resistance. Cancer Res.
70:4602–4612. 2010. View Article : Google Scholar : PubMed/NCBI
|
